TNFRSF1B and nonpapillary renal cell carcinoma: We recently reported that selective ligation of TNFR2 can drive the cell‐cycle entry of CD133+CSCs isolated from ccRCC (ccRCC‐CD133+CSCs), rendering them sensitive to killing by a chemotherapeutic agent.21 The current investigation was initiated to understand the mechanism through which TNFR2 acts.